untitled
<OAI-PMH schemaLocation=http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd>
<responseDate>2018-01-15T18:33:13Z</responseDate>
<request identifier=oai:HAL:hal-00875083v1 verb=GetRecord metadataPrefix=oai_dc>http://api.archives-ouvertes.fr/oai/hal/</request>
<GetRecord>
<record>
<header>
<identifier>oai:HAL:hal-00875083v1</identifier>
<datestamp>2017-12-21</datestamp>
<setSpec>type:ART</setSpec>
<setSpec>subject:sdv</setSpec>
<setSpec>collection:UNIV-AG</setSpec>
<setSpec>collection:UNIV-NANTES</setSpec>
<setSpec>collection:UNIV-PARIS7</setSpec>
<setSpec>collection:IFR140</setSpec>
<setSpec>collection:UPMC</setSpec>
<setSpec>collection:IRSET</setSpec>
<setSpec>collection:UNIV-RENNES1</setSpec>
<setSpec>collection:APHP</setSpec>
<setSpec>collection:IRSET-HIAEC</setSpec>
<setSpec>collection:BIOSIT</setSpec>
<setSpec>collection:UR1-UFR-SVE</setSpec>
<setSpec>collection:USPC</setSpec>
<setSpec>collection:HL</setSpec>
<setSpec>collection:UR1-HAL</setSpec>
<setSpec>collection:EHESP</setSpec>
<setSpec>collection:STATS-UR1</setSpec>
<setSpec>collection:UR1-SDV</setSpec>
<setSpec>collection:IRSET-2</setSpec>
<setSpec>collection:UNIV-ANGERS</setSpec>
</header>
<metadata><dc>
<publisher>HAL CCSD</publisher>
<title lang=en>A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.</title>
<creator>Marcelin, Anne-Geneviève</creator>
<creator>Delaugerre, Constance</creator>
<creator>Beaudoux, Céline</creator>
<creator>Descamps, Diane</creator>
<creator>Morand-Joubert, Laurence</creator>
<creator>Amiel, Corinne</creator>
<creator>Schneider, Veronique</creator>
<creator>Ferre, Virginie</creator>
<creator>Izopet, Jacques</creator>
<creator>Si-Mohamed, Ali</creator>
<creator>Maillard, Anne</creator>
<creator>Henquell, Cécile</creator>
<creator>Desbois, Delphine</creator>
<creator>Lazrek, Mouna</creator>
<creator>Signori-Schmuck, Anne</creator>
<creator>Rogez, Sylvie</creator>
<creator>Yerly, Sabine</creator>
<creator>Trabaud, Mary-Anne</creator>
<creator>Plantier, Jean-Christophe</creator>
<creator>Fourati, Slim</creator>
<creator>Houssaini, Allal</creator>
<creator>Masquelier, Bernard</creator>
<creator>Calvez, Vincent</creator>
<creator>Flandre, Philippe</creator>
<creator>Michelet, Christian</creator>
<contributor>Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH ; Université Pierre et Marie Curie - Paris 6 (UPMC) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales ; Université Paris Diderot - Paris 7 (UPD7) - Institut National de la Santé et de la Recherche Médicale (INSERM)</contributor>
<contributor>Laboratoire de Virologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Bichat - Claude Bernard [Paris]</contributor>
<contributor>Service de bactériologie-virologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Saint-Antoine [APHP]</contributor>
<contributor>Service de virologie ; Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Tenon [APHP]</contributor>
<contributor>CHU Nantes ; Université de Nantes (UN)</contributor>
<contributor>Laboratoire de Virologie [Purpan] ; CHU Toulouse [Toulouse] - Hôpital Purpan - Institut Fédératif de Biologie (IFB)</contributor>
<contributor>CHU Pontchaillou [Rennes]</contributor>
<contributor>Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)</contributor>
<contributor>Service de Bactériologie, Virologie, Hygiène [CHU Limoges] ; CHU Limoges</contributor>
<contributor>Unité de virologie générale ; Hôpital Charles Nicolle - CHU Rouen - Département de microbiologie : Bactério, Virologie, Parasito, Hygiène</contributor>
<contributor>Service de virologie et d'immunologie biologique ; CHU Bordeaux [Bordeaux] - Groupe hospitalier Pellegrin</contributor>
<contributor>Institut de recherche, santé, environnement et travail [Rennes] (Irset) ; Université d'Angers (UA) - Université des Antilles et de la Guyane (UAG) - Université de Rennes 1 (UR1) - École des Hautes Études en Santé Publique [EHESP] (EHESP) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )</contributor>
<description>International audience</description>
<source>ISSN: 0924-8579</source>
<source>International Journal of Antimicrobial Agents</source>
<publisher>Elsevier</publisher>
<identifier>hal-00875083</identifier>
<identifier>https://hal.archives-ouvertes.fr/hal-00875083</identifier>
<source>https://hal.archives-ouvertes.fr/hal-00875083</source>
<source>International Journal of Antimicrobial Agents, Elsevier, 2013, 42 (1), pp.42-7. 〈10.1016/j.ijantimicag.2013.02.016〉</source>
<identifier>DOI : 10.1016/j.ijantimicag.2013.02.016</identifier>
<relation>info:eu-repo/semantics/altIdentifier/doi/10.1016/j.ijantimicag.2013.02.016</relation>
<identifier>PUBMED : 23562640</identifier>
<relation>info:eu-repo/semantics/altIdentifier/pmid/23562640</relation>
<language>en</language>
<subject lang=en>Integrase</subject>
<subject lang=en>Inhibitor</subject>
<subject lang=en>Raltegravir</subject>
<subject lang=en>Mutations</subject>
<subject lang=en>Efficacy</subject>
<subject lang=en>HIV-1</subject>
<subject lang=en>Response</subject>
<subject>[SDV.MP] Life Sciences [q-bio]/Microbiology and Parasitology</subject>
<type>info:eu-repo/semantics/article</type>
<type>Journal articles</type>
<description lang=en>This study aimed to identify factors associated with virological response (VR) to raltegravir (RAL)-containing regimens in 468 treatment-experienced but integrase inhibitor-naive HIV-1 patients receiving a RAL-containing regimen. VR was defined at Month 6 (M6) as HIV-1 RNA viral load (VL) <50 copies/mL. The impacts on VR of baseline integrase mutations, VL, CD4 count, genotypic sensitivity score for nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and protease inhibitors, and the number of new antiretrovirals used for the first time associated with RAL were investigated. For patients with VL >50 copies/mL at M6, integrase mutations selected were characterised. Median baseline VL was 4.2 log(10)copies/mL (IQR 3.3-4.9 log(10) copies/mL) and CD4 count was 219 cells/mm(3) (IQR 96-368 cells/mm(3)). At M6, 71% of patients were responders. In multivariate analysis, baseline VL and CD4 count and ≥ 2 new antiretrovirals among darunavir, etravirine, maraviroc and enfuvirtide were associated with VR to RAL. Neither HIV-1 subtype nor baseline integrase polymorphisms were associated with VR to RAL. Among 63 failing patients at M6, selection of ≥ 1 change in the integrase gene was observed in 49 (77.8%), and 27/63 (42.9%) were considered as RAL-associated resistance mutations. Factors independently associated with the occurrence of ≥ 1 RAL-associated resistance mutation were VL at failure >3 log(10) and having no new drugs associated with RAL. RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR.</description>
<contributor>ANRS AC11 Resistance Group</contributor>
<date>2013-07</date>
</dc>
</metadata>
</record>
</GetRecord>
</OAI-PMH>
